(HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a ...

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological ...

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer's, and Parkinson's disease continues to rise, especially for MS ...

In addition, these factors also stimulate inflammation-related damage to the nervous system, contributing to ...

Professor Andrew Abell, Department of Chemistry and the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Institute for Photonics and ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

Managing blood pressure is critical to maintaining overall health, especially as we age. High blood pressure, often referred ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...

THE RISING global prevalence of youth-onset Type 2 diabetes (Y-T2D) is a serious public health concern. With an aggressive ...

NEW RESEARCH presented at EASD 2024 revealed that maternal Type 1 diabetes (T1D) provides long-term relative protection ...